Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CYTK
CYTK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CYTK News
Cytokinetics to Host Third Annual Muscle Biology Symposium
May 14 2026
Newsfilter
Cytokinetics Presents Favorable Clinical Data for MYQORZO at ESC Heart Failure 2026
May 11 2026
Newsfilter
Cytokinetics Closes $805 Million Public Offering
May 08 2026
Newsfilter
Cytokinetics Raises $700M in Upsized Public Offering
May 07 2026
seekingalpha
Cytokinetics Prices $700 Million Public Offering at $71 per Share
May 07 2026
Newsfilter
CYTOKINETICS INC: B. RILEY INCREASES TARGET PRICE FROM $108.00 TO $146.00
May 06 2026
moomoo
Cytokinetics Reports Strong Q1 2026 Earnings with MYQORZO Launch Success
May 06 2026
seekingalpha
Cytokinetics (CYTK) Q1 2026 Earnings Transcript
May 05 2026
NASDAQ.COM
Cytokinetics Inc. Announces $650 Million Common Stock Offering in SEC Filing
May 05 2026
moomoo
Rockwell Automation Surges on Strong Q2 Earnings Beat
May 05 2026
CNBC
Cytokinetics' Heart Drug Trial Success Boosts Stock
May 05 2026
stocktwits
Cytokinetics Shares Surge 23% on Positive Phase 3 Trial Results
May 05 2026
NASDAQ.COM
Cytokinetics Stock Rises 23.7% in Premarket Trading Following Successful Late-Stage Heart Disease Drug Trial Results
May 05 2026
moomoo
Cytokinetics Reports Positive Results from ACACIA-HCM Trial
May 05 2026
Newsfilter
Cytokinetics Reports Encouraging Topline Findings from ACACIA-HCM, a Key Phase 3 Trial of Aficamten for Non-Obstructive Hypertrophic Cardiomyopathy Patients
May 05 2026
moomoo
Cytokinetics Set to Announce Q1 Earnings on May 5th
May 04 2026
seekingalpha
Show More News
